Meeting Register Page

Meet the Trialists: How will DOSE-VF potentially change resuscitation practice?
Join the AHA for a virtual conversation from 9 to 10 a.m. ET November 11 to hear from the investigators of a significant study published in the New England Journal of Medicine that showed double sequential external defibrillation (DSED) was associated with higher survival-to-hospital discharge with good neurologic function compared to standard defibrillation for cardiac arrest patients with refractory ventricular fibrillation. Furthermore, vector-change defibrillation was shown to be superior compared to standard defibrillation for termination of ventricular fibrillation and survival-to-hospital discharge.

Lead author, Sheldon Cheskes, MD, and co-senior author, Paul Dorian, MD will discuss the trial findings. AHA volunteer, Ash Panchal, MD, who also leads the Science Subcommittee of the AHA’s Emergency Cardiovascular Care (ECC) division, and Mark Link, MD, a longstanding AHA volunteer, will serve as the discussants. Sarah Perman, MD, MSCE, an AHA volunteer in ECC and 3CPR Council, will moderate a live Q&A with the authors.

This important conversation will cover the following:
• Overview of the DOSE-VF trial
• How double sequential external defibrillation and vector-change defibrillation were performed in the trial
• Potential impact for treating out-of-hospital cardiac arrest patients
• Live Q&A with the speakers

Shortly after you register for this virtual event, Zoom will send a registration confirmation email.

To read the NEJM study, go to

To read the accompanying NEJM editorial about the study, go to

Nov 11, 2022 08:00 AM in Central Time (US and Canada)

* Required information